


## Avasimibe

<b>Cat. No.:</b>	HY-13215		
<b>CAS No.:</b>	166518-60-1		
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>43</sub> NO <sub>4</sub> S		
<b>Molecular Weight:</b>	501.72		
<b>Target:</b>	Acyltransferase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 28 mg/mL (55.81 mM)  
 H<sub>2</sub>O : < 0.1 mg/mL (insoluble)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
	1 mM		1.9931 mL	9.9657 mL	19.9314 mL
	5 mM		0.3986 mL	1.9931 mL	3.9863 mL
	10 mM		0.1993 mL	0.9966 mL	1.9931 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: 2.08 mg/mL (4.15 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: 2.25 mg/mL (4.48 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.08 mg/mL (4.15 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Avasimibe is an oral inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT) with IC<sub>50</sub>s of 24 and 9.2 μM for ACAT1 and ACAT2, respectively.

### CUSTOMER VALIDATION

- 
- Biomed Pharmacother. 2020 Jul 16;130:110508.
  - Oncol Lett. 2019 Aug;18(2):1548-1556.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Tardif JC et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. *Circulation*, 2004 Nov 23, 110(21):3372-7.
- [2]. Raal FJ et al. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. *Atherosclerosis*, 2003 Dec, 171(2):273-9.
- [3]. Delsing DJ et al. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE\*3-Leiden mice. *Circulation*, 2001 Apr 3, 103(13):1778-86.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA